Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs)

Biodexa Ltd, a clinical stage biopharmaceutical company, has successfully completed the enrollment and treatment phase of the Phase 1 study for MTX110. This study focused on treating children with newly diagnosed Diffuse Midline Gliomas (DMGs), a type of primary brain tumor that primarily affects children and has a poor prognosis. The study took place at Columbia University Irving Medical Centre..